Asthma affects over 2 million Malaysians, with prevalence rates as high as 9.4% in children and 5% in adults, according to recent national health surveys. Despite this significant burden, diagnosing and managing it effectively remains a challenge. Recognizing this critical gap, Mediven brings the UBREATH FeNO Breath Gas Analysis System to Malaysia—a non-invasive, high-precision diagnostic tool that is transforming the way clinicians manage respiratory diseases.
Fractional exhaled Nitric Oxide (FeNO) is a well-established biomarker for airway inflammation. Elevated FeNO levels often signal uncontrolled asthma or the need for anti-inflammatory treatment. Unlike traditional spirometry, FeNO testing offers a direct, quantifiable measure of airway inflammation, helping clinicians fine-tune therapies, monitor disease progression, and reduce exacerbation risks, especially in children and pregnant women.
UBREATH: Advanced Technology in a Compact Form
The UBREATH FeNO Analyzer, CE-marked and registered with the Malaysian Medical Device Authority (MDA), is tailored for healthcare professionals seeking rapid, reliable, and patient-friendly asthma diagnostics.
Key Features Include:
- Rapid test results within minutes
- Wide FeNO measurement range
- Dual-mode operation for both adults and children
- Multiple analysis capabilities for flexible clinical applications
The UBREATH® FeNO Analyzer is backed by a strong foundation of international and local clinical guidelines, reinforcing its role as a trusted tool in asthma diagnosis and management. It is supported by the Global Initiative for Asthma (GINA), the UK’s National Institute for Health and Care Excellence (NICE), and leading respiratory bodies such as the European Respiratory Society (ERS), American Thoracic Society (ATS), and British Thoracic Society (BTS). Locally, it aligns with Malaysia’s Clinical Practice Guidelines for Asthma, which underscore the importance of accurate and non-invasive tools in asthma care.
These guidelines emphasize FeNO testing as an essential component for diagnosing and managing asthma, particularly in complex or ambiguous cases. Unlike traditional methods that rely solely on symptom reporting or spirometry, FeNO testing provides a direct, quantifiable measurement of airway inflammation. Clinical studies have demonstrated that FeNO-guided treatment strategies can lead to a reduction in asthma exacerbations by up to 50%, while significantly improving diagnostic accuracy—with reported sensitivities of up to 99% and specificities of 95%. These outcomes highlight the superiority of FeNO testing in guiding more personalized, effective, and timely asthma interventions.
By integrating FeNO testing through advanced systems like UBREATH, clinicians are better equipped to deliver more personalized, evidence-based care for asthma patients. As respiratory diseases continue to pose significant challenges to public health, embracing innovations like UBREATH—in partnership with Mediven—represents a step forward in early diagnosis, optimized treatment strategies, and ultimately, better quality of life for patients across Malaysia and beyond. Together, we can reshape the future of respiratory care with precision, clarity, and confidence.
